Navigation Links
Reportlinker Adds Pipeline Insight: Cancer Overview- Breast and Gynecological Cancers - Promising agents emerge for BRCA positive patients
Date:2/15/2011

NEW YORK, Feb. 15, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pipeline Insight: Cancer Overview- Breast and Gynecological Cancers - Promising agents emerge for BRCA positive patients

http://www.reportlinker.com/p0386436/Pipeline-Insight-Cancer-Overview--Breast-and-Gynecological-Cancers---Promising-agents-emerge-for-BRCA-positive-patients.html

Introduction

The three tumor types covered in this report are set to account for just over 585,000 new cancer cases in 2010 with forecasts of over 656,000 new cases in 2019. Collectively the drugs profiled in this report for breast and ovarian cancer are forecast to achieve almost $3.0 billion in sales in the seven major pharmaceutical markets in 2019.

Scope of this research

Examination of the breast and ovarian cancer pipelines with in-depth clinical and commercial profiles of Phase III candidates Seven major pharmaceutical market sales forecasts for Phase III pipeline products through to 2019 with product-specific assumptions Segmentation and analysis of the current breast and ovarian cancer pipelines by phase of development, drug class and company Insight and analysis of breast, ovarian and cervical cancer markets including commercial opportunity, epidemiology and discussion of unmet needs Research and analysis highlights

There are currently 94 drugs in clinical development for breast cancer, of which 8 are in late phase development (preregistration, Phase III or pivotal Phase II trial). Collectively, the drugs forecast in this report for breast cancer are forecast to achieve $1.1 billion in sales by 2019.

There are currently 41 drugs in the pipeline for ovarian cancer, of which 10 are in late-phase development. Collectively, the drugs in late-phase development for ovarian cancer profiled in this report are forecast to achieve $1.8bn in sales by 2019.

R&D interest in cervical cancer is limited compared with other cancers and as a result there is a lack of novel drug candidates in late-phase development. Despite poor outcomes and prognoses for late-stage patients, recent focus has been directed towards preventative strategies rather than treatment.

Key reasons to purchase this research

Identify key drugs within the breast and ovarian cancer pipelines based on sales forecasts and Datamonitor drug assessment Characterize unmet needs within breast, ovarian and cervical cancers and assess the potential for pipeline products to fulfill them Assess the shifting breast, ovarian and cervical cancer market dynamics and how future treatment will incorporate pipeline products

To order this report:

: Pipeline Insight: Cancer Overview- Breast and Gynecological Cancers - Promising agents emerge for BRCA positive patients

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Reportlinker Adds Strategic Analysis of European Human Machine Interface (HMI) Market
2. Reportlinker Adds Amphotericin B - Comprehensive patent search
3. Reportlinker Adds Therapeutic Proteins to 2014
4. Reportlinker Adds Biochips - Products, Applications, Technologies and End-Use Markets Growth Analysis, 2009-2015
5. Reportlinker Adds Cell Therapy - Technologies, Markets and Companies
6. Reportlinker Adds The 2011 Molecular Diagnostics Market: DNA Probes and Biochips -- New Product Development Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers
7. Reportlinker Adds The 2011 Immunoprotein Diagnostics Market: US, Europe, Japan Test Volume and Sales Forecasts by Country and Market Segment
8. Reportlinker Adds The 2011 Clinical Chemistry and Immunodiagnostics Markets: US, Europe, Japan Product Development Opportunities and Business Expansion Strategies for Instrumentand Reagent Suppliers
9. Reportlinker Adds Biologic Therapeutic Drugs: Technologies and Global Markets
10. Reportlinker Adds The Future of In Vitro and In Vivo Diagnostic Integration
11. Reportlinker Adds Vaccine Technologies and Global Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
(Date:6/23/2016)... June 23, 2016  The Prostate Cancer Foundation (PCF) is pleased ... and faster cures for prostate cancer. Members of the Class of 2016 were ... Read More About the Class of 2016 PCF Young ... ... ...
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
Breaking Biology Technology:
(Date:5/16/2016)... NEW YORK , May 16, 2016   ... authentication solutions, today announced the opening of an IoT ... to strengthen and expand the development of embedded ... provides an unprecedented level of convenience and security with ... to authenticate one,s identity aside from DNA. EyeLock,s platform ...
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
Breaking Biology News(10 mins):